Citation Impact
Citing Papers
Conformal piezoelectric energy harvesting and storage from motions of the heart, lung, and diaphragm
2014 Standout
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Using naso- and oro-intestinal catheters in physiological research for intestinal delivery and sampling in vivo: practical and technical aspects to be considered.
2021
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Genetic basis for individual variations in pain perception and the development of a chronic pain condition
2004 Standout
Combined Use of the Adenosine A2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys
2000
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study
2010
Drug-Induced Hepatotoxicity
2003 Standout
Gut microbiome and health: mechanistic insights
2022 Standout
Therapeutics of Alzheimer's disease: Past, present and future
2013
Evidence‐Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
2008
Tolcapone and Hepatotoxic Effects
2000
Rivastigmine for Alzheimer's disease
2000
Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
2012 Standout
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
2004 Standout
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
2013 Standout
Effects of entacapone and tolcapone on mitochondrial membrane potential
2002
The construct of resilience: Implications for interventions and social policies
2000
Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson???s Disease
2000
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
2020 Standout
Ventricular wall stress.
1981
Pharmacotherapeutic strategies in the treatment of severe Alzheimer’s disease
2016
Diastolic retroperfusion of acutely ischemic myocardium
1976
Psychological Resilience
2013 Standout
Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer’s disease
2017
The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs.
1977 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Gut microbiota are related to Parkinson's disease and clinical phenotype
2014 Standout
ProTox-II: a webserver for the prediction of toxicity of chemicals
2018 Standout
Constitutive modelling of passive myocardium: a structurally based framework for material characterization
2009 Standout
Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors
1999
An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine
2018
Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
2008
ADOLESCENT RESILIENCE: A Framework for Understanding Healthy Development in the Face of Risk
2004 Standout
Evaluation of Several Geometric Models for Estimation of Left Ventricular Circumferential Wall Stress
1973
Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
2020 Standout
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
2018 Standout
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
2001 Standout
Rivastigmine for Alzheimer's disease
2015
Cholinesterase inhibitors for Alzheimer's disease
2006 Standout
Works of G Sędek being referenced
Pharmacokinetics of a Rivastigmine Transdermal Patch Formulation in Healthy Volunteers: Relative Effects of Body Site Application
2007
Pharmacokinetics and Pharmacodynamics of the Novel Daily Rivastigmine Transdermal Patch Compared With Twice-daily Capsules in Alzheimer's Disease Patients
2007
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
1998
Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects
2008
Estimation of the Absolute Bioavailability of Rivastigmine in Patients with Mild to Moderate Dementia of the Alzheimer???s Type
2002
Effect of Tolcapone on Plasma Levodopa Concentrations after Coadministration with Levodopa/Carbidopa to Healthy Volunteers
1997
Absorption of Rivastigmine from Different Regions of the Gastrointestinal Tract in Humans
2004
Multiple-dose clinical pharmacology of the catechol- O -methyl-transferase inhibitor tolcapone in elderly subjects
1996
Uncontrollability, depression, and the construction of mental models.
1999
529. Pharmacokinetics of rivastigmine and its metabolite in patients with Alzheimer’s disease
2000
Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa.
1995
Direct measurement of tension within left ventricular wall of the dog heart
1972